Physician profile
Deepak Sobti
NPI 1790002814
$25,598.89
in general payments reported to CMS, 2019-2025
20 companies · $21K in 2025
The $21K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $233 · 2021: $376 · 2022: $1,520 · 2023: $1,143 · 2024: $1,335 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $4,310 · Entertainment: $106 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,645.00 |
| Food and Beverage | $4,309.52 |
| Entertainment | $106.36 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $20,289.99 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $2,350.60 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $889.11 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Alcon Vision LLC | $740.46 | 2019-2025 | Clareon, Argos, Wavelight Refractive Suite |
| Allergan, INC. | $243.29 | 2020-2022 | |
| Abbvie INC. | $229.59 | 2022-2025 | |
| Carl Zeiss Meditec USA, INC. | $158.17 | 2021-2023 | Callisto Eye |
| Amgen INC. | $145.29 | 2024-2025 | Tepezza |
| Optos, INC. | $106.36 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $96.08 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $73.61 | 2021 | |
| Beaver-Visitec International, INC. | $58.30 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $50.70 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $37.98 | 2019 | |
| Horizon Therapeutics Plc | $34.06 | 2023 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $22.53 | 2025 | Dextenza |
| Dompe US, INC. | $20.46 | 2024 | Oxervate |
| Rayner Intraocular Lenses Limited | $19.57 | 2022 | |
| Sight Sciences, INC. | $17.47 | 2022 | |
| Lensar, INC. | $15.27 | 2025 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Sobti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.